Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

5 source entries across 5 studies. This list may not include all unresolved or historical entries.

  • ALGRX 4975Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • ALGRX 4975Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • ALGRX 4975Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • ALGRX 4975Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • ALGRX 4975Registry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Phase 2
5
100%

Phase Distribution

0

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
5(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(5)

Detailed Status

Completed5

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 25 (100.0%)

Trials by Status

completed5100%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_2

ALGRX 4975 in the Treatment of Tennis Elbow

NCT00130949
completedphase_2

ALGRX 4975 After Total Knee Replacement

NCT00132392
completedphase_2

Efficacy and Safety of ALGRX 4975 in the Treatment of Postoperative Pain After Gall Bladder Removal

NCT00133133
completedphase_2

Efficacy and Safety of ALGRX 4975 in Treatment of Postoperative Pain After Hernia Repair

NCT00146198
completedphase_2

ALGRX 4975 in the Treatment of Patients With Morton's Neuroma

NCT00130962

Clinical Trials (5)

Showing 5 of 5 trials
NCT00130949Phase 2

ALGRX 4975 in the Treatment of Tennis Elbow

Completed
NCT00132392Phase 2

ALGRX 4975 After Total Knee Replacement

Completed
NCT00133133Phase 2

Efficacy and Safety of ALGRX 4975 in the Treatment of Postoperative Pain After Gall Bladder Removal

Completed
NCT00146198Phase 2

Efficacy and Safety of ALGRX 4975 in Treatment of Postoperative Pain After Hernia Repair

Completed
NCT00130962Phase 2

ALGRX 4975 in the Treatment of Patients With Morton's Neuroma

Completed

All 5 trials loaded

Drug Details

Intervention Type
Drug
Total Trials
5